FDA 483 - Cipla Limited - November 13, 2019

Cipla, Ltd. in Raigad, Maharashtra, was cited for significant quality control and data integrity issues during an FDA inspection. Observations included failures in thoroughly investigating out-of-specification results, releasing API batches without proper investigation, and a lack of authority within the quality control unit. Additionally, employees demonstrated inadequate training regarding data integration and audit trail review.